Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Blake Marriott

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Drug Targets. Immune, Endocrine and Metabolic Disorders|July 23, 2003
Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agentsJ Blake Marriott, Keith Dredge, Angus G Dalgleish
Current Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
Angiogenesis inhibitors in cancer therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Expert Opinion on Biological Therapy|January 9, 2003
Recent developments in antiangiogenic therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Critical Reviews in Immunology|June 14, 2003
Immunological effects of thalidomide and its chemical and functional analogsKeith Dredge, J Blake Marriott, Angus G Dalgleish
Anti-Cancer Drugs|June 5, 2003
Thalidomide analogs as emerging anti-cancer drugsKeith Dredge, Angus G Dalgleish, J Blake Marriott
Cancer Immunology, Immunotherapy : CII|October 18, 2002
Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapyKeith Dredge, J Blake Marriott, Stephen M Todryk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2002
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunityKeith Dredge, J Blake Marriott, Stephen M Todryk, et al.
Cancer Research|February 5, 2003
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteinsJ Blake Marriott, Ian A Clarke, Anna Czajka, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Drug Targets. Immune, Endocrine and Metabolic Disorders|July 23, 2003
Thalidomide derived immunomodulatory drugs (IMiDs) as potential therapeutic agentsJ Blake Marriott, Keith Dredge, Angus G Dalgleish
Current Opinion in Investigational Drugs (London, England : 2000)|August 7, 2003
Angiogenesis inhibitors in cancer therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Expert Opinion on Biological Therapy|January 9, 2003
Recent developments in antiangiogenic therapyKeith Dredge, Angus G Dalgleish, J Blake Marriott
Critical Reviews in Immunology|June 14, 2003
Immunological effects of thalidomide and its chemical and functional analogsKeith Dredge, J Blake Marriott, Angus G Dalgleish
Anti-Cancer Drugs|June 5, 2003
Thalidomide analogs as emerging anti-cancer drugsKeith Dredge, Angus G Dalgleish, J Blake Marriott
Cancer Immunology, Immunotherapy : CII|October 18, 2002
Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapyKeith Dredge, J Blake Marriott, Stephen M Todryk, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 8, 2002
Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunityKeith Dredge, J Blake Marriott, Stephen M Todryk, et al.
Cancer Research|February 5, 2003
A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteinsJ Blake Marriott, Ian A Clarke, Anna Czajka, et al.
Pageof 1